Ajanta Pharma Ltd vs Gujarat Themis Biosyn Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 03, 2026

Key Highlights

The Latest Trading Price of Ajanta Pharma Ltd is ₹ 2824 as of 30 Apr 15:30 . The P/E Ratio of Ajanta Pharma Ltd changed from 23.9 on March 2021 to 35.7 on March 2025 . This represents a CAGR of 8.36% over 5 yearsThe P/E Ratio of Gujarat Themis Biosyn Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Ajanta Pharma Ltd changed from ₹ 15517 crore on March 2021 to ₹ 32708 crore on March 2025 . This represents a CAGR of 16.08% over 5 yearsThe Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Ajanta Pharma Ltd for the Dec '25 is ₹ 1399 crore as compare to the Sep '25 revenue of ₹ 1413 crore. This represent the decline of -0.94% The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Ajanta Pharma Ltd for the Dec '25 is ₹ 407.21 crore as compare to the Sep '25 ebitda of ₹ 387.17 crore. This represent the growth of 5.18% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Ajanta Pharma Ltd changed from ₹ 245.77 crore to ₹ 273.77 crore over 7 quarters. This represents a CAGR of 6.36% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The Dividend Payout of Ajanta Pharma Ltd changed from 12.23 % on March 2021 to 38.28 % on March 2025 . This represents a CAGR of 25.63% over 5 yearsThe Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 years .

About Ajanta Pharma Ltd

Ajanta Pharma Limited is a specialty pharmaceutical formulation company primarily with a well-diversified Branded Generics business spread across India, the Rest of Asia, and Africa.
The Company is involved in development, manufacturing and marketing of quality finished dosages in domestic and international markets.
It produces a comprehensive range of specialty products targeting different therapeutic segments.
It has strong chronic-focused product portfolio led by a first-to-market strategy and front-end presence which helps it outgrow the market. The company's business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales.
The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia.

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

FAQs for the comparison of Ajanta Pharma Ltd and Gujarat Themis Biosyn Ltd

Which company has a larger market capitalization, Ajanta Pharma Ltd or Gujarat Themis Biosyn Ltd?

Market cap of Ajanta Pharma Ltd is 35,289 Cr while Market cap of Gujarat Themis Biosyn Ltd is 3,963 Cr

What are the key factors driving the stock performance of Ajanta Pharma Ltd and Gujarat Themis Biosyn Ltd?

The stock performance of Ajanta Pharma Ltd and Gujarat Themis Biosyn Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Ajanta Pharma Ltd and Gujarat Themis Biosyn Ltd?

As of May 3, 2026, the Ajanta Pharma Ltd stock price is INR ₹2824.6. On the other hand, Gujarat Themis Biosyn Ltd stock price is INR ₹363.75.

How do dividend payouts of Ajanta Pharma Ltd and Gujarat Themis Biosyn Ltd compare?

To compare the dividend payouts of Ajanta Pharma Ltd and Gujarat Themis Biosyn Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.